These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 28502672

  • 1. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
    Podolski-Renić A, Banković J, Dinić J, Ríos-Luci C, Fernandes MX, Ortega N, Kovačević-Grujičić N, Martín VS, Padrón JM, Pešić M.
    Eur J Pharm Sci; 2017 Jul 15; 105():159-168. PubMed ID: 28502672
    [Abstract] [Full Text] [Related]

  • 2. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
    Bai Z, Gao M, Zhang H, Guan Q, Xu J, Li Y, Qi H, Li Z, Zuo D, Zhang W, Wu Y.
    Cancer Lett; 2017 Aug 28; 402():81-92. PubMed ID: 28576750
    [Abstract] [Full Text] [Related]

  • 3. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
    Dinić J, Ríos-Luci C, Karpaviciene I, Cikotiene I, Fernandes MX, Pešić M, Padrón JM.
    Invest New Drugs; 2020 Jun 28; 38(3):584-598. PubMed ID: 31177401
    [Abstract] [Full Text] [Related]

  • 4. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
    Bai Z, Liu X, Guan Q, Ding N, Wei Q, Tong B, Zhao M, Zhang W, Ma L.
    Chem Biol Interact; 2020 Jan 05; 315():108886. PubMed ID: 31682804
    [Abstract] [Full Text] [Related]

  • 5. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
    Yi JM, Zhang XF, Huan XJ, Song SS, Wang W, Tian QT, Sun YM, Chen Y, Ding J, Wang YQ, Yang CH, Miao ZH.
    Oncotarget; 2015 Apr 20; 6(11):8960-73. PubMed ID: 25840421
    [Abstract] [Full Text] [Related]

  • 6. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P, Lu P, Sharom FJ, Fang WS.
    Cancer Lett; 2013 Dec 01; 341(2):214-23. PubMed ID: 23941826
    [Abstract] [Full Text] [Related]

  • 7. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
    Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, Lloyd DG, Campiani G, Lawler M, Williams DC, Zisterer DM.
    Cancer Chemother Pharmacol; 2010 Aug 01; 66(3):585-96. PubMed ID: 20020128
    [Abstract] [Full Text] [Related]

  • 8. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
    Meng F, Cai X, Duan J, Matteucci MG, Hart CP.
    Cancer Chemother Pharmacol; 2008 May 01; 61(6):953-63. PubMed ID: 17639393
    [Abstract] [Full Text] [Related]

  • 9. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
    Tripathi S, Srivastava G, Sharma A.
    Biochem Biophys Res Commun; 2016 Aug 05; 476(4):273-279. PubMed ID: 27233604
    [Abstract] [Full Text] [Related]

  • 10. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
    Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W.
    Mol Pharmacol; 2019 Jul 05; 96(1):73-89. PubMed ID: 31043459
    [Abstract] [Full Text] [Related]

  • 11. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.
    Am J Obstet Gynecol; 2013 Jul 05; 209(1):62.e1-9. PubMed ID: 23583215
    [Abstract] [Full Text] [Related]

  • 12. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
    Wang H, Vo T, Hajar A, Li S, Chen X, Parissenti AM, Brindley DN, Wang Z.
    BMC Cancer; 2014 Jan 22; 14():37. PubMed ID: 24447372
    [Abstract] [Full Text] [Related]

  • 13. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
    Li CM, Lu Y, Chen J, Costello TA, Narayanan R, Dalton MN, Snyder LM, Ahn S, Li W, Miller DD, Dalton JT.
    Pharm Res; 2012 Nov 22; 29(11):3053-63. PubMed ID: 22760659
    [Abstract] [Full Text] [Related]

  • 14. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A, Katayama R, Oh-Hara T, Sato S, Okuno Y, Fujita N.
    Mol Cancer Ther; 2014 Dec 22; 13(12):2978-90. PubMed ID: 25313010
    [Abstract] [Full Text] [Related]

  • 15. 4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
    Lin MS, Hong TM, Chou TH, Yang SC, Chung WC, Weng CW, Tsai ML, Cheng TR, Chen JJW, Lee TC, Wong CH, Chein RJ, Yang PC.
    Eur J Med Chem; 2019 Nov 01; 181():111584. PubMed ID: 31419740
    [Abstract] [Full Text] [Related]

  • 16. MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells.
    Lee WH, Liu HE, Chang JY, Liou JP, Huang HM.
    Pharmacology; 2013 Nov 01; 92(1-2):90-8. PubMed ID: 23949011
    [Abstract] [Full Text] [Related]

  • 17. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T, Lin S, Ji M, Xue N, Liu Y, Zhang Z, Zhang K, Zhang J, Zhang Y, Wang Q, Sheng L, Li Y, Lu D, Chen X, Xu H.
    Cancer Lett; 2020 Dec 28; 495():22-32. PubMed ID: 32931884
    [Abstract] [Full Text] [Related]

  • 18. Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
    Sobue S, Mizutani N, Aoyama Y, Kawamoto Y, Suzuki M, Nozawa Y, Ichihara M, Murate T.
    Biochem Biophys Res Commun; 2016 Oct 28; 479(4):808-813. PubMed ID: 27687545
    [Abstract] [Full Text] [Related]

  • 19. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
    Yang J, Yan W, Yu Y, Wang Y, Yang T, Xue L, Yuan X, Long C, Liu Z, Chen X, Hu M, Zheng L, Qiu Q, Pei H, Li D, Wang F, Bai P, Wen J, Ye H, Chen L.
    J Biol Chem; 2018 Jun 15; 293(24):9461-9472. PubMed ID: 29691282
    [Abstract] [Full Text] [Related]

  • 20. High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.
    Pera B, Calvo-Vidal MN, Ambati S, Jordi M, Kahn A, Díaz JF, Fang W, Altmann KH, Cerchietti L, Moore MAS.
    Cancer Lett; 2015 Nov 01; 368(1):97-104. PubMed ID: 26277539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.